<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02317627</url>
  </required_header>
  <id_info>
    <org_study_id>KD025-206</org_study_id>
    <nct_id>NCT02317627</nct_id>
  </id_info>
  <brief_title>Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy</brief_title>
  <official_title>A Phase 2, Open-Label, Dose-finding Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kadmon Corporation, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kadmon Corporation, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was performed to evaluate the safety, tolerability, activity, pharmacokinetics&#xD;
      (PK), and daily dose regimen of KD025 administered orally (PO) for 12 weeks to subjects with&#xD;
      psoriasis vulgaris who failed at least one line of systemic therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study KD025-206 was a phase 2, open-label, dose-finding, safety, tolerability, activity, and&#xD;
      PK study of KD025 in subjects with psoriasis who had failed at least 1 line of systemic&#xD;
      therapy or phototherapy.&#xD;
&#xD;
      Subjects received KD025 PO for 12 weeks. Planned enrollment was 36 subjects in 3 cohorts, 12&#xD;
      subjects per cohort:&#xD;
&#xD;
        -  Cohort 1 (12 subjects): KD025 400 mg once daily (QD) PO for 12 weeks&#xD;
&#xD;
        -  Cohort 2 (12 subjects): KD025 200 mg PO twice daily (BID) for 12 weeks&#xD;
&#xD;
        -  Cohort 3 (12 subjects): KD025 400 mg BID PO for 12 weeks&#xD;
&#xD;
      Subjects were initially enrolled simultaneously in Cohort 1 and Cohort 2 according to a&#xD;
      randomization schedule, with safety reviewed before any subjects. If safety guidelines were&#xD;
      met, Cohort 3 was added to explore the efficacy and safety of KD025 at a dose of 400 mg PO&#xD;
      BID.&#xD;
&#xD;
      Subjects underwent safety evaluations: medical history evaluations; physical examinations&#xD;
      (PEs); vital sign measurements; weight measurements; adverse event (AE) assessments;&#xD;
      concomitant medication assessments; blood sample collection for hematology, chemistry, and&#xD;
      coagulation; lipid panel; thyroid-stimulating hormone; measurements of antinuclear antibody;&#xD;
      anti-double-stranded deoxyribonucleic acid; Complement C; antiphospholipid antibody; liver&#xD;
      ultrasound (US); pregnancy testing for females of childbearing potential; PK sampling (subset&#xD;
      of subjects only); urinalysis; and electrocardiogram (ECG).&#xD;
&#xD;
      Subjects underwent efficacy evaluations: Psoriasis Area and Severity Index (PASI) scoring;&#xD;
      Physicians Global Assessment (PGA) scoring; and Dermatologic Life Quality Index (DLQI)&#xD;
      scoring.&#xD;
&#xD;
      Subjects participating in PK sampling were admitted to the clinic on Month 1 Day 1 (M1D1) for&#xD;
      PK procedures and were discharged on M2D2. Blood samples for PK analyses were collected on&#xD;
      M2D1 and Month 3 Day 1 (M3D1) on an outpatient basis. Subjects were not to take their morning&#xD;
      dose until after blood samples were drawn.&#xD;
&#xD;
      A Follow-Up visit occurred 30 ± 3 days after the last dose of study drug.&#xD;
&#xD;
      The endpoints for efficacy were PASI, PGA, and DSQI scores.&#xD;
&#xD;
        1. Psoriasis Area and Severity Index (PASI): The PASI is a measure of the psoriasis disease&#xD;
           severity using the average redness, thickness, and scaliness of the lesions (each graded&#xD;
           on a 0 to 4 scale), which is weighted by the area of involvement. The PASI combines the&#xD;
           assessment of the severity of lesions and the area affected into a single score ranging&#xD;
           from 0 (no disease) to 72 (maximal disease).&#xD;
&#xD;
        2. Physicians Global Assessment (PGA): The relative PGA documents the physician's&#xD;
           assessment of the subject's psoriasis status. Consideration was given to the percent of&#xD;
           body involvement as well as overall induration, scaling, and erythema. The PGA was&#xD;
           assessed relative to baseline condition and defined as: (1) clear; (2) excellent; (3)&#xD;
           good; (4) fair; (5) poor; and (6) worse.&#xD;
&#xD;
        3. Dermatology Life Quality Index (DLQI): The DLQI is a skin disease-specific instrument&#xD;
           designed to assess the impact of the disease on a subject's quality of life (QOL). It is&#xD;
           a 10-item questionnaire that assesses 6 different aspects of quality of life: symptoms&#xD;
           and feelings, daily activities, leisure, work or school performance, personal&#xD;
           relationships, and treatment. Possible DLQI scores range from 0 (no detectable&#xD;
           impairment on a subject's QOL) to 30 (extremely large effect on a subject's QOL).&#xD;
&#xD;
      Safety was assessed by standard clinical and laboratory tests (hematology, serum chemistry,&#xD;
      and urinalysis), PEs, and reporting of treatment-emergent adverse events (TEAEs). Toxicity&#xD;
      grades were defined using the National Cancer Institute (NCI) Common Terminology Criteria for&#xD;
      Adverse Events (CTCAE) Version 5.0. In addition, subjects had liver ultrasound and liver&#xD;
      functioning testing assessed for possible steatosis.&#xD;
&#xD;
      Blood samples for determination of PK plasma concentrations of KD025 and its metabolites were&#xD;
      collected for maximum concentration (Cmax); time of maximum concentration (Tmax); area under&#xD;
      the concentration-time curve (AUC) at 0 to 24 hours, 0 to last, and 0 to infinity (0 to 24, 0&#xD;
      to last, 0 to infinity [inf]); half-life (t1/2); and accumulation ratio (metabolic-to-parent&#xD;
      drug ratio).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease in PASI Score at EOT---ITT Population</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of available subjects who achieved at least a 75% reduction (PASI 75) or at least a 50% reduction from baseline in Psoriasis Area and Severity Index (PASI) score after 12 weeks of treatment with belumosudil or at the end of treatment with belumosudil in the Intent-to-Treat Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease With PASI Score at EOT---Evaluable Population</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of available subjects who achieved at least a 75% reduction and a 50% reduction from baseline in Psoriasis Area and Severity Index score at end of treatment with belumosudil in the Evaluable Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Percentage of Subjects With AEs by Severity and Relationship to Belumosudil--ITT Population</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of subjects who had an adverse event by severity in the Intent-to-Treat Population: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death.&#xD;
Percentage of subjects who had an adverse event by relationship to belumosudil in the Intent-to-Treat Population as assessed by the investigator: definitely related, probably related, possibly related, and not related to belumosudil.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Mean Change in PASI Score at 12 Weeks From Baseline--ITT Population</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean change in Psoriasis Area and Severity Index score after 12 weeks of treatment or End of Treatment with KD025 from baseline in the Intent-to-Treat Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.] Negative mean change is favorable; positive mean change is unfavorable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Mean Change in PASI Score at 12 Weeks From Baseline--Evaluable Population</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean change in Psoriasis Area and Severity Index score after 12 weeks of treatment or end of treatment with belumosudil from baseline in the Evaluable Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.] Negative mean change is favorable; positive mean change is unfavorable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percentage of Subjects With a Decrease in PASI After 4 Weeks---ITT Population</measure>
    <time_frame>4 weeks</time_frame>
    <description>The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline after 4 weeks of treatment with belumosudil in the Intent-to-Treat Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percentage of Subjects With a Decrease in PASI Score After 8 Weeks---ITT Population</measure>
    <time_frame>8 weeks</time_frame>
    <description>The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline after 8 weeks of treatment with belumosudil in the Intent-to-Treat Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percentage of Subjects With a Decrease in PASI Score at EOT---ITT Population</measure>
    <time_frame>12 weeks</time_frame>
    <description>The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline at the end of treatment with belumosudil in the Intent-to-Treat Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percentage of Subjects With a Decrease in PASI Score After 4 Weeks, 8 Weeks, and 12 Weeks---Evaluable Population</measure>
    <time_frame>12 weeks</time_frame>
    <description>The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline after 4 weeks, 8 weeks, and 12 weeks of treatment with belumosudil in the Evaluable Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Mean Change in PASI Score After 4 Weeks---ITT Population</measure>
    <time_frame>4 weeks</time_frame>
    <description>Mean change in the Psoriasis Area and Severity Index score from baseline after 4 weeks of treatment with belumosudil in the Intent-to-Treat Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.] Negative mean change is favorable; positive mean change is unfavorable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Mean Change in PASI Score After 8 Weeks---ITT Population</measure>
    <time_frame>8 weeks</time_frame>
    <description>Mean change in the Psoriasis Area and Severity Index score from baseline after 8 weeks of treatment with belumosudil in the Intent-to-Treat Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.] Negative mean change is favorable; positive mean change is unfavorable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Mean Change in PASI Score at 4 and 8 Weeks---Evaluable Population</measure>
    <time_frame>8 weeks</time_frame>
    <description>Mean change in the Psoriasis Area and Severity Index score from baseline after 4 and 8 weeks of treatment with belumosudil in the Evaluable Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.] Negative mean change is favorable; positive mean change is unfavorable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percentage of Subjects With Improvement in PGA af 4 Weeks---ITT Population</measure>
    <time_frame>4 weeks</time_frame>
    <description>Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 4 weeks of treatment with belumosudil in the Intent-to-Treat Population.&#xD;
The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percentage of Subjects With Improvement in PGA af 8 Weeks---ITT Population</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 8 weeks of treatment with belumosudil in the Intent-to-Treat Population.&#xD;
The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse.&#xD;
PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percentage of Subjects With Improvement in PGA af EOT--ITT Population</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 12 weeks of treatment with belumosudil or at the end of treatment (EOT) in the Intent-to-Treat Population.&#xD;
The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse.&#xD;
PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Percentage of Subjects With Improvement in PGA af 4, 8, and 12 Weeks---Evaluable Population</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 4 weeks, after 8 weeks, and after 12 week of treatment with belumosudil in the Evaluable Population.&#xD;
The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse.&#xD;
PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Mean Changes in DLQI at EOT--ITT Population</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean changes in the Dermatology Life Quality Index from baseline after 12 weeks of treatment with belumosudil or end of treatment with KD025 in the Intent-to-Treat Population [The Dermatology Life Quality Index (DLQI) is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. The scale range is 0 to 30: 0-1=no effect on subject's quality of life; 2-5=small effect; 6-10= moderate effect; 11-20=very large effect; 21-30=extremely large effect.] Negative mean change is favorable; positive mean change is unfavorable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Mean Changes in DLQI at 12 Weeks--Evaluable Population</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean changes in the Dermatology Life Quality Index (DLQI) score from baseline after 12 weeks of treatment with belumosudil in the Evaluable Population.&#xD;
[The Dermatology Life Quality Index (DLQI) is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. The scale range is 0 to 30: 0-1=no effect on subject's quality of life; 2-5=small effect; 6-10= moderate effect; 11-20=very large effect; 21-30=extremely large effect.] Negative mean change is favorable; positive mean change is unfavorable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Cmax of Parent Drug KD025, KD025m1, and KD025m2</measure>
    <time_frame>24 hours</time_frame>
    <description>Maximum concentration (Cmax) of Parent drug (KD0250), Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: AUC of Parent Drug KD025, KD025m1, and KD025m2</measure>
    <time_frame>24 hours</time_frame>
    <description>Area Under Concentration Time Curve (AUC) for Parent Drug KD025, Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2):&#xD;
AUC(0-12) = AUC from predose to 12 hours post-dose AUC(0-24) = AUC from predose to 24 hours post-dose AUC(0-t) = AUC from predose to a given time &quot;t&quot; post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: t(1/2) of KD025</measure>
    <time_frame>24 hours</time_frame>
    <description>Half-life (t[1/2]) of Parent drug (KD025)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: MR C(Max) and MR AUC(0-t) for KD025m1 and KD025m2</measure>
    <time_frame>24 hours</time_frame>
    <description>Metabolite-to-parent ratio of maximum concentration (MR C[max]) and metabolite-to-parent ratio of the area under concentration time curve from pre-dose to a given time &quot;t&quot; for Metabolite 1 (KD025m1) and Metabolite 2 (KD025m2)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KD025 400 mg QD PO for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KD025 200 mg BID PO for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KD025 400 mg BID PO for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KD025</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>SLx-2119</other_name>
    <other_name>belumosudil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to provide written informed consent prior to the performance of any study&#xD;
             specific procedures&#xD;
&#xD;
          -  Diagnosis of moderately severe plaque psoriasis that has been moderately stable for 6&#xD;
             months and failed at least 1 line of systemic or phototherapy and is a candidate for&#xD;
             additional systemic therapy&#xD;
&#xD;
          -  PASI of ≥ 12 within the 24-hour period prior to the first dose of study drug&#xD;
&#xD;
          -  At least 10% of body surface area affected by plaque psoriasis within the 24-hour&#xD;
             period prior to the first dose of study drug&#xD;
&#xD;
          -  Willing to avoid tanning devices&#xD;
&#xD;
          -  Willing to forgo other systemic and topical treatments for psoriasis during the course&#xD;
             of the study&#xD;
&#xD;
          -  Adequate bone marrow function: absolute neutrophil count &gt; 1500/mm^3; hemoglobin &gt; 9.0&#xD;
             g/dL; platelets &gt; 100,000/mm^3&#xD;
&#xD;
          -  Negative urine pregnancy test (for women of childbearing potential) documented within&#xD;
             the 24-hour period prior to the first dose of study drug&#xD;
&#xD;
          -  Agree to use a highly effective method of birth control (&lt; 1% per year failure rate)&#xD;
             during the study and for 1 month after the termination of the study. Effective birth&#xD;
             control included implants, injectables, combined oral contraceptives, some IUDs,&#xD;
             sexual abstinence, or vasectomized partner&#xD;
&#xD;
          -  Willing to complete all study measurements and assessments in compliance with the&#xD;
             protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-plaque or drug-induced (antimalarials, lithium) psoriasis (If subject is taking&#xD;
             angiotensin II receptor blockers or beta blockers doses had to be stable for 6 months&#xD;
             prior to study entry)&#xD;
&#xD;
          -  Use of corticosteroid or immunosuppressive therapy within 4 weeks prior to study entry&#xD;
             except for Class 5 or weaker topical corticosteroids or immunosuppressive therapies to&#xD;
             the face, groin, or scalp.&#xD;
&#xD;
          -  Use of methotrexate, acitretin, or cyclosporine within 4 weeks prior to study entry&#xD;
&#xD;
          -  Use of phototherapy within 4 weeks prior to study entry&#xD;
&#xD;
          -  Use of biologic therapies, including antibodies to IL-17, within 3 months prior to&#xD;
             study entry&#xD;
&#xD;
          -  Concomitant condition requiring treatment with moderate to high dose steroids in the&#xD;
             12 weeks prior to screening&#xD;
&#xD;
          -  Viral, fungal, or bacterial skin infection&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  History of gastrointestinal (GI) surgery including bariatric surgery, or any GI&#xD;
             condition that might interfere with drug absorption&#xD;
&#xD;
          -  Currently participating in another study with an investigational drug or within 28&#xD;
             days of study entry&#xD;
&#xD;
          -  History or other evidence of severe illness or any other conditions that would make&#xD;
             the subject, in the opinion of the investigator, unsuitable for the study (such as&#xD;
             poorly controlled psychiatric disease or coronary artery disease)&#xD;
&#xD;
          -  Regular and excessive use of alcohol within the 2 years prior to study entry defined&#xD;
             as alcohol intake &gt; 14 drinks per week in a man or &gt; 7 drinks per week in a woman.&#xD;
             Approximately 10 g of alcohol equals one &quot;drink&quot; unit. One unit equals 1 ounce of&#xD;
             distilled spirits, one 12-ounce beer, or one 4-ounce glass of wine&#xD;
&#xD;
          -  History or presence of any of the following:&#xD;
&#xD;
               1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 2.0 × the&#xD;
                  upper limit of normal (ULN) at screening. (Subjects with an isolated AST&#xD;
                  elevation of any magnitude, or a ratio of AST:ALT &gt; 1.5 interviewed regarding use&#xD;
                  of alcohol, have levels repeated and participation in the study should be&#xD;
                  discussed with the medical monitor.)&#xD;
&#xD;
               2. Renal disease and/or serum creatinine &gt; 1.5 × ULN at screening&#xD;
&#xD;
          -  QTc(F) interval (QT interval data corrected using Fridericia's formula) &gt; 450 msec at&#xD;
             the screening or predose ECG&#xD;
&#xD;
          -  Previous exposure to KD025 or known allergy/sensitivity to KD025 or any other ROCK-2&#xD;
             inhibitor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arrowhead Health Centers</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern California Dermatology, Inc.</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shondra L. Smith</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Studies Group, LLC</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>High Point Clinical Trials Center</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metroplex Clinical Research Center (MCRC)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 10, 2014</study_first_submitted>
  <study_first_submitted_qc>December 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2014</study_first_posted>
  <results_first_submitted>August 13, 2021</results_first_submitted>
  <results_first_submitted_qc>October 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 1, 2021</results_first_posted>
  <disposition_first_submitted>April 6, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>April 6, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 4, 2016</disposition_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>400 mg QD</title>
          <description>Belumosudil 400 mg administered orally (PO) once daily (QD) for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>200 mg BID</title>
          <description>Belumosudil 200 mg administered PO twice daily (BID) for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>400 mg BID</title>
          <description>Belumosudil 400 mg administered PO BID for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Stopped by Investigator</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-Treat (ITT) defined as all subjects enrolled in the study</population>
      <group_list>
        <group group_id="B1">
          <title>400 mg QD</title>
          <description>Belumosudil 400 mg PO QD for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>200 mg BID</title>
          <description>Belumosudil 200 mg PO BID for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>400 mg BID</title>
          <description>Belumosudil 400 mg PO BID for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.6" spread="10.32"/>
                    <measurement group_id="B2" value="46.5" spread="11.92"/>
                    <measurement group_id="B3" value="50.5" spread="10.26"/>
                    <measurement group_id="B4" value="47.1" spread="10.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.0" lower_limit="29" upper_limit="60"/>
                    <measurement group_id="B2" value="45.0" lower_limit="25" upper_limit="67"/>
                    <measurement group_id="B3" value="54.5" lower_limit="30" upper_limit="64"/>
                    <measurement group_id="B4" value="47.5" lower_limit="25" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (body mass index)--Mean</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.42" spread="7.132"/>
                    <measurement group_id="B2" value="32.81" spread="7.747"/>
                    <measurement group_id="B3" value="32.65" spread="10.582"/>
                    <measurement group_id="B4" value="33.31" spread="8.362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI--Median</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.70" lower_limit="22.2" upper_limit="45.4"/>
                    <measurement group_id="B2" value="31.40" lower_limit="23.4" upper_limit="51.4"/>
                    <measurement group_id="B3" value="30.35" lower_limit="22.7" upper_limit="63.8"/>
                    <measurement group_id="B4" value="31.50" lower_limit="22.2" upper_limit="63.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Psoriasis Area and Severity Index (PASI) Score--Mean</title>
          <description>The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.0" spread="10.85"/>
                    <measurement group_id="B2" value="18.3" spread="8.51"/>
                    <measurement group_id="B3" value="20.3" spread="7.24"/>
                    <measurement group_id="B4" value="19.8" spread="8.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PASI--Median</title>
          <description>The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.</description>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.0" lower_limit="12.8" upper_limit="52.8"/>
                    <measurement group_id="B2" value="16.2" lower_limit="12.0" upper_limit="42.0"/>
                    <measurement group_id="B3" value="18.5" lower_limit="12.9" upper_limit="32.2"/>
                    <measurement group_id="B4" value="17.3" lower_limit="12.0" upper_limit="52.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physician Global Assessment (PGA)</title>
          <description>The Physician Global Assessment (PGA) documents the physician's assessment of the subject's psoriasis and is assessed relative to baseline conditions. The PGA rating is from 1-6, where 1 = 100% clearing of psoriasis (clear), 5 = 0 to 24% clearing (little or no change), and 6 = worse.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Clear (100%)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Excellent (75% to 99%)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Good (50% to 74%)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fair (25% to 49%)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Poor (0% to 24%)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worse</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dermatology Quality Life Index (DQLI)--Mean</title>
          <description>The Dermatology Life Quality Index (DLQI) is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. The scale range is 0 to 30: 0-1=no effect on subject's life; 2-5=small effect; 6-10= moderate effect; 11-20=very large effect; 21-30=extremely large effect.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.6" spread="6.79"/>
                    <measurement group_id="B2" value="14.2" spread="6.39"/>
                    <measurement group_id="B3" value="10.3" spread="7.77"/>
                    <measurement group_id="B4" value="13.1" spread="7.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>DLQI--Median</title>
          <description>The Dermatology Life Quality Index (DLQI) is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. The scale range is 0 to 30: 0-1=no effect on subject's life; 2-5=small effect; 6-10= moderate effect; 11-20=very large effect; 21-30=extremely large effect.</description>
          <units>Units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.0" lower_limit="5" upper_limit="26"/>
                    <measurement group_id="B2" value="15.0" lower_limit="4" upper_limit="28"/>
                    <measurement group_id="B3" value="10.0" lower_limit="0" upper_limit="27"/>
                    <measurement group_id="B4" value="12.5" lower_limit="0" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease in PASI Score at EOT---ITT Population</title>
        <description>Percentage of available subjects who achieved at least a 75% reduction (PASI 75) or at least a 50% reduction from baseline in Psoriasis Area and Severity Index (PASI) score after 12 weeks of treatment with belumosudil or at the end of treatment with belumosudil in the Intent-to-Treat Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.]</description>
        <time_frame>12 weeks</time_frame>
        <population>Intent-to-Treat (ITT) Population: All subjects enrolled in study</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg QD</title>
            <description>Belumosudil 400 mg PO QD for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>200 mg BID</title>
            <description>Belumosudil 200 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>400 mg BID</title>
            <description>Belumosudil 400 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Overall (All Subjects)</title>
            <description>Belumosudil 400 mg QD + 200 mg QD + 400 mg BID for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease in PASI Score at EOT---ITT Population</title>
          <description>Percentage of available subjects who achieved at least a 75% reduction (PASI 75) or at least a 50% reduction from baseline in Psoriasis Area and Severity Index (PASI) score after 12 weeks of treatment with belumosudil or at the end of treatment with belumosudil in the Intent-to-Treat Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.]</description>
          <population>Intent-to-Treat (ITT) Population: All subjects enrolled in study</population>
          <units>Percentage of participants (%)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥ 75% Reduction from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="2.1" upper_limit="48.4"/>
                    <measurement group_id="O2" value="8.3" lower_limit="0.2" upper_limit="38.5"/>
                    <measurement group_id="O3" value="9.1" lower_limit="0.2" upper_limit="41.3"/>
                    <measurement group_id="O4" value="11.4" lower_limit="3.2" upper_limit="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 50% Reduction from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7" lower_limit="15.2" upper_limit="72.3"/>
                    <measurement group_id="O2" value="50.0" lower_limit="21.1" upper_limit="78.9"/>
                    <measurement group_id="O3" value="18.2" lower_limit="2.3" upper_limit="51.8"/>
                    <measurement group_id="O4" value="37.1" lower_limit="21.5" upper_limit="55.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease With PASI Score at EOT---Evaluable Population</title>
        <description>Percentage of available subjects who achieved at least a 75% reduction and a 50% reduction from baseline in Psoriasis Area and Severity Index score at end of treatment with belumosudil in the Evaluable Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.]</description>
        <time_frame>12 weeks</time_frame>
        <population>Evaluable Population: Subjects who receive at least 80% of the expected amount of study drug if the subject had completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg QD</title>
            <description>Belumosudil 400 mg PO QD for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>200 mg BID</title>
            <description>Belumosudil 200 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>400 mg BID</title>
            <description>Belumosudil 400 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Overall (All Subjects)</title>
            <description>Belumosudil 400 mg QD + 200 mg QD + 400 mg BID for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Percentage of Subjects With ≥ 75% Decrease or ≥ 50% Decrease With PASI Score at EOT---Evaluable Population</title>
          <description>Percentage of available subjects who achieved at least a 75% reduction and a 50% reduction from baseline in Psoriasis Area and Severity Index score at end of treatment with belumosudil in the Evaluable Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.]</description>
          <population>Evaluable Population: Subjects who receive at least 80% of the expected amount of study drug if the subject had completed the study</population>
          <units>Percentage of participants (%)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>≥ 75% Reduction from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="2.1" upper_limit="48.4"/>
                    <measurement group_id="O2" value="14.3" lower_limit="0.4" upper_limit="57.9"/>
                    <measurement group_id="O3" value="14.3" lower_limit="0.4" upper_limit="57.9"/>
                    <measurement group_id="O4" value="15.4" lower_limit="4.4" upper_limit="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 50% Reduction from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7" lower_limit="15.2" upper_limit="72.3"/>
                    <measurement group_id="O2" value="71.4" lower_limit="29.0" upper_limit="96.3"/>
                    <measurement group_id="O3" value="28.6" lower_limit="3.7" upper_limit="71.0"/>
                    <measurement group_id="O4" value="46.2" lower_limit="26.6" upper_limit="66.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety: Percentage of Subjects With AEs by Severity and Relationship to Belumosudil--ITT Population</title>
        <description>Percentage of subjects who had an adverse event by severity in the Intent-to-Treat Population: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death.&#xD;
Percentage of subjects who had an adverse event by relationship to belumosudil in the Intent-to-Treat Population as assessed by the investigator: definitely related, probably related, possibly related, and not related to belumosudil.</description>
        <time_frame>12 weeks</time_frame>
        <population>ITT Population: All enrolled subjects</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg QD</title>
            <description>Belumosudil 400 mg PO QD for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>200 mg BID</title>
            <description>Belumosudil 200 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>400 mg BID</title>
            <description>Belumosudil 400 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Overall (All Subjects)</title>
            <description>Belumosudil 400 mg QD + 200 mg QD + 400 mg BID for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Percentage of Subjects With AEs by Severity and Relationship to Belumosudil--ITT Population</title>
          <description>Percentage of subjects who had an adverse event by severity in the Intent-to-Treat Population: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death.&#xD;
Percentage of subjects who had an adverse event by relationship to belumosudil in the Intent-to-Treat Population as assessed by the investigator: definitely related, probably related, possibly related, and not related to belumosudil.</description>
          <population>ITT Population: All enrolled subjects</population>
          <units>Percentage of participants (%)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1 (Mild)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2"/>
                    <measurement group_id="O2" value="46.2"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 (Moderate)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2"/>
                    <measurement group_id="O2" value="46.2"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="55.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 (Severe)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="7.7"/>
                    <measurement group_id="O3" value="8.3"/>
                    <measurement group_id="O4" value="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 (Life-threatening)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 5 (Death)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related to KD025</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5"/>
                    <measurement group_id="O2" value="23.1"/>
                    <measurement group_id="O3" value="58.3"/>
                    <measurement group_id="O4" value="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3, 4, or 5 Related to KD025</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Mean Change in PASI Score at 12 Weeks From Baseline--ITT Population</title>
        <description>Mean change in Psoriasis Area and Severity Index score after 12 weeks of treatment or End of Treatment with KD025 from baseline in the Intent-to-Treat Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.] Negative mean change is favorable; positive mean change is unfavorable</description>
        <time_frame>12 weeks</time_frame>
        <population>Intent-to-Treat (ITT) Population: All enrolled subjects</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg QD</title>
            <description>Belumosudil 400 mg PO QD for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>200 mg BID</title>
            <description>Belumosudil 200 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>400 mg BID</title>
            <description>Belumosudil 400 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Overall (All Subjects)</title>
            <description>Belumosudil 400 mg QD + 200 mg QD + 400 mg BID for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Mean Change in PASI Score at 12 Weeks From Baseline--ITT Population</title>
          <description>Mean change in Psoriasis Area and Severity Index score after 12 weeks of treatment or End of Treatment with KD025 from baseline in the Intent-to-Treat Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.] Negative mean change is favorable; positive mean change is unfavorable</description>
          <population>Intent-to-Treat (ITT) Population: All enrolled subjects</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>End of Treatment (or 12 Weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" lower_limit="7.9" upper_limit="17.0"/>
                    <measurement group_id="O2" value="10.3" lower_limit="7.0" upper_limit="13.6"/>
                    <measurement group_id="O3" value="14.4" lower_limit="8.8" upper_limit="19.9"/>
                    <measurement group_id="O4" value="12.3" lower_limit="9.9" upper_limit="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at End of Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" lower_limit="-16.5" upper_limit="-1.1"/>
                    <measurement group_id="O2" value="-6.0" lower_limit="-9.5" upper_limit="-2.4"/>
                    <measurement group_id="O3" value="-4.8" lower_limit="-8.9" upper_limit="-0.7"/>
                    <measurement group_id="O4" value="-6.6" lower_limit="-9.5" upper_limit="-3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change in Cohort 400 mg QD PASI from baseline to Week 12.</non_inferiority_desc>
            <p_value>0.0282</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change in Cohort 200 mg BID PASI from baseline to Week 12.</non_inferiority_desc>
            <p_value>0.0035</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change in Cohort 400 mg BID PASI from baseline to Week 12.</non_inferiority_desc>
            <p_value>0.0261</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change for all subjects' PASI from baseline to Week 12.</non_inferiority_desc>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Mean Change in PASI Score at 12 Weeks From Baseline--Evaluable Population</title>
        <description>Mean change in Psoriasis Area and Severity Index score after 12 weeks of treatment or end of treatment with belumosudil from baseline in the Evaluable Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.] Negative mean change is favorable; positive mean change is unfavorable</description>
        <time_frame>12 weeks</time_frame>
        <population>Intent-to-Treat (ITT) Population: All enrolled subjects</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg QD</title>
            <description>Belumosudil 400 mg PO QD for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>200 mg BID</title>
            <description>Belumosudil 200 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>400 mg BID</title>
            <description>Belumosudil 400 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Overall (All Subjects)</title>
            <description>Belumosudil 400 mg QD + 200 mg QD + 400 mg BID for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Mean Change in PASI Score at 12 Weeks From Baseline--Evaluable Population</title>
          <description>Mean change in Psoriasis Area and Severity Index score after 12 weeks of treatment or end of treatment with belumosudil from baseline in the Evaluable Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.] Negative mean change is favorable; positive mean change is unfavorable</description>
          <population>Intent-to-Treat (ITT) Population: All enrolled subjects</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" lower_limit="7.9" upper_limit="17.0"/>
                    <measurement group_id="O2" value="7.6" lower_limit="5.6" upper_limit="9.6"/>
                    <measurement group_id="O3" value="15.5" lower_limit="5.8" upper_limit="25.1"/>
                    <measurement group_id="O4" value="12.0" lower_limit="8.9" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at 12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" lower_limit="-16.5" upper_limit="-1.1"/>
                    <measurement group_id="O2" value="-7.9" lower_limit="-11.9" upper_limit="-3.9"/>
                    <measurement group_id="O3" value="-5.9" lower_limit="-12.5" upper_limit="0.7"/>
                    <measurement group_id="O4" value="-7.8" lower_limit="-11.4" upper_limit="-4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change in Cohort 400 mg QD PASI from baseline to Week 12.</non_inferiority_desc>
            <p_value>0.0282</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change in Cohort 200 mg BID PASI from baseline to Week 12.</non_inferiority_desc>
            <p_value>0.0029</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change in Cohort 400 mg BID PASI from baseline to Week 12.</non_inferiority_desc>
            <p_value>0.0703</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change of all subjects' PASI from baseline to Week 12.</non_inferiority_desc>
            <p_value>0.0002</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Percentage of Subjects With a Decrease in PASI After 4 Weeks---ITT Population</title>
        <description>The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline after 4 weeks of treatment with belumosudil in the Intent-to-Treat Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.]</description>
        <time_frame>4 weeks</time_frame>
        <population>Intent-to-Treat (ITT) Population: All enrolled subjects</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg QD</title>
            <description>Belumosudil 400 mg PO QD for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>200 mg BID</title>
            <description>Belumosudil 200 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>400 mg BID</title>
            <description>Belumosudil 400 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Overall (All Subjects)</title>
            <description>Belumosudil 400 mg QD + 200 mg QD + 400 mg BID for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Percentage of Subjects With a Decrease in PASI After 4 Weeks---ITT Population</title>
          <description>The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline after 4 weeks of treatment with belumosudil in the Intent-to-Treat Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.]</description>
          <population>Intent-to-Treat (ITT) Population: All enrolled subjects</population>
          <units>Percentage of participants (%)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9" lower_limit="46.2" upper_limit="95.0"/>
                    <measurement group_id="O2" value="66.7" lower_limit="34.9" upper_limit="90.1"/>
                    <measurement group_id="O3" value="58.3" lower_limit="27.7" upper_limit="84.8"/>
                    <measurement group_id="O4" value="67.6" lower_limit="50.2" upper_limit="82.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Percentage of Subjects With a Decrease in PASI Score After 8 Weeks---ITT Population</title>
        <description>The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline after 8 weeks of treatment with belumosudil in the Intent-to-Treat Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.]</description>
        <time_frame>8 weeks</time_frame>
        <population>Intent-to-Treat (ITT) Population: All enrolled subjects</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg QD</title>
            <description>Belumosudil 400 mg PO QD for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>200 mg BID</title>
            <description>Belumosudil 200 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>400 mg BID</title>
            <description>Belumosudil 400 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Overall (All Subjects)</title>
            <description>Belumosudil 400 mg QD + 200 mg QD + 400 mg BID for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Percentage of Subjects With a Decrease in PASI Score After 8 Weeks---ITT Population</title>
          <description>The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline after 8 weeks of treatment with belumosudil in the Intent-to-Treat Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.]</description>
          <population>Intent-to-Treat (ITT) Population: All enrolled subjects</population>
          <units>Percentage of participants (%)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="51.6" upper_limit="97.9"/>
                    <measurement group_id="O2" value="100" lower_limit="66.4" upper_limit="100"/>
                    <measurement group_id="O3" value="85.7" lower_limit="42.1" upper_limit="99.6"/>
                    <measurement group_id="O4" value="89.3" lower_limit="71.8" upper_limit="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Percentage of Subjects With a Decrease in PASI Score at EOT---ITT Population</title>
        <description>The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline at the end of treatment with belumosudil in the Intent-to-Treat Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.]</description>
        <time_frame>12 weeks</time_frame>
        <population>Intent-to-Treat (ITT) Population: All enrolled subjects</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg QD</title>
            <description>Belumosudil 400 mg PO QD for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>200 mg BID</title>
            <description>Belumosudil 200 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>400 mg BID</title>
            <description>Belumosudil 400 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Overall (All Subjects)</title>
            <description>Belumosudil 400 mg QD + 200 mg QD + 400 mg BID for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Percentage of Subjects With a Decrease in PASI Score at EOT---ITT Population</title>
          <description>The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline at the end of treatment with belumosudil in the Intent-to-Treat Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.]</description>
          <population>Intent-to-Treat (ITT) Population: All enrolled subjects</population>
          <units>Percentage of participants (%)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="42.8" upper_limit="94.5"/>
                    <measurement group_id="O2" value="75.0" lower_limit="42.8" upper_limit="94.5"/>
                    <measurement group_id="O3" value="81.8" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O4" value="77.1" lower_limit="59.9" upper_limit="89.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Percentage of Subjects With a Decrease in PASI Score After 4 Weeks, 8 Weeks, and 12 Weeks---Evaluable Population</title>
        <description>The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline after 4 weeks, 8 weeks, and 12 weeks of treatment with belumosudil in the Evaluable Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.]</description>
        <time_frame>12 weeks</time_frame>
        <population>Evaluable Population: Subjects who received at least 80% of the expected amount study drug if the subject had completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg QD</title>
            <description>Belumosudil 400 mg PO QD for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>200 mg BID</title>
            <description>Belumosudil 200 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>400 mg BID</title>
            <description>Belumosudil 400 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Overall (All Subjects)</title>
            <description>Belumosudil 400 mg QD + 200 mg QD + 400 mg BID for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Percentage of Subjects With a Decrease in PASI Score After 4 Weeks, 8 Weeks, and 12 Weeks---Evaluable Population</title>
          <description>The percentage of subjects who exhibit any decrease in the Psoriasis Area and Severity Index score from baseline after 4 weeks, 8 weeks, and 12 weeks of treatment with belumosudil in the Evaluable Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.]</description>
          <population>Evaluable Population: Subjects who received at least 80% of the expected amount study drug if the subject had completed the study</population>
          <units>Percentage of participants (%)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="42.8" upper_limit="94.5"/>
                    <measurement group_id="O2" value="85.7" lower_limit="42.1" upper_limit="99.6"/>
                    <measurement group_id="O3" value="71.4" lower_limit="29.0" upper_limit="96.3"/>
                    <measurement group_id="O4" value="76.9" lower_limit="56.4" upper_limit="91.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" lower_limit="51.6" upper_limit="97.9"/>
                    <measurement group_id="O2" value="100" lower_limit="59.0" upper_limit="100"/>
                    <measurement group_id="O3" value="85.7" lower_limit="42.1" upper_limit="99.6"/>
                    <measurement group_id="O4" value="88.5" lower_limit="69.8" upper_limit="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="42.8" upper_limit="94.5"/>
                    <measurement group_id="O2" value="100" lower_limit="59.0" upper_limit="100"/>
                    <measurement group_id="O3" value="85.7" lower_limit="42.1" upper_limit="99.6"/>
                    <measurement group_id="O4" value="84.6" lower_limit="65.1" upper_limit="95.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Mean Change in PASI Score After 4 Weeks---ITT Population</title>
        <description>Mean change in the Psoriasis Area and Severity Index score from baseline after 4 weeks of treatment with belumosudil in the Intent-to-Treat Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.] Negative mean change is favorable; positive mean change is unfavorable</description>
        <time_frame>4 weeks</time_frame>
        <population>Intent-to-Treat (ITT) Population: All enrolled subjects</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg QD</title>
            <description>Belumosudil 400 mg PO QD for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>200 mg BID</title>
            <description>Belumosudil 200 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>400 mg BID</title>
            <description>Belumosudil 400 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Overall (All Subjects)</title>
            <description>Belumosudil 400 mg QD + 200 mg QD + 400 mg BID for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Mean Change in PASI Score After 4 Weeks---ITT Population</title>
          <description>Mean change in the Psoriasis Area and Severity Index score from baseline after 4 weeks of treatment with belumosudil in the Intent-to-Treat Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.] Negative mean change is favorable; positive mean change is unfavorable</description>
          <population>Intent-to-Treat (ITT) Population: All enrolled subjects</population>
          <units>Score on a scale</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" lower_limit="-7.8" upper_limit="-1.6"/>
                    <measurement group_id="O2" value="-2.6" lower_limit="-5.3" upper_limit="0"/>
                    <measurement group_id="O3" value="-2.3" lower_limit="-5.5" upper_limit="1.0"/>
                    <measurement group_id="O4" value="-3.2" lower_limit="-4.8" upper_limit="-1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change in Cohort 400 mg QD from baseline to Week 4.</non_inferiority_desc>
            <p_value>0.0064</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change in Cohort 200 mg BID from baseline to Week 4.</non_inferiority_desc>
            <p_value>0.0479</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change in Cohort 400 mg BID from baseline to Week 4.</non_inferiority_desc>
            <p_value>0.1513</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change Overall from baseline to Week 4.</non_inferiority_desc>
            <p_value>0.0002</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Mean Change in PASI Score After 8 Weeks---ITT Population</title>
        <description>Mean change in the Psoriasis Area and Severity Index score from baseline after 8 weeks of treatment with belumosudil in the Intent-to-Treat Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.] Negative mean change is favorable; positive mean change is unfavorable</description>
        <time_frame>8 weeks</time_frame>
        <population>Intent-to-Treat (ITT) Population: All enrolled subjects</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg QD</title>
            <description>Belumosudil 400 mg PO QD for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>200 mg BID</title>
            <description>Belumosudil 200 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>400 mg BID</title>
            <description>Belumosudil 400 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Overall (All Subjects)</title>
            <description>Belumosudil 400 mg QD + 200 mg QD + 400 mg BID for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Mean Change in PASI Score After 8 Weeks---ITT Population</title>
          <description>Mean change in the Psoriasis Area and Severity Index score from baseline after 8 weeks of treatment with belumosudil in the Intent-to-Treat Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.] Negative mean change is favorable; positive mean change is unfavorable</description>
          <population>Intent-to-Treat (ITT) Population: All enrolled subjects</population>
          <units>Score on a scale</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" lower_limit="-15.0" upper_limit="-2.1"/>
                    <measurement group_id="O2" value="-6.4" lower_limit="-9.6" upper_limit="-3.2"/>
                    <measurement group_id="O3" value="-4.7" lower_limit="-10.0" upper_limit="0.6"/>
                    <measurement group_id="O4" value="-6.9" lower_limit="-9.8" upper_limit="-4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change in Cohort 400 mg QD from baseline to Week 8.</non_inferiority_desc>
            <p_value>0.0137</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change in Cohort 200 mg BID from baseline to Week 8.</non_inferiority_desc>
            <p_value>0.0017</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change in Cohort 400 mg BID from baseline to Week 8.</non_inferiority_desc>
            <p_value>0.0743</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change Overall from baseline to Week 8.</non_inferiority_desc>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Mean Change in PASI Score at 4 and 8 Weeks---Evaluable Population</title>
        <description>Mean change in the Psoriasis Area and Severity Index score from baseline after 4 and 8 weeks of treatment with belumosudil in the Evaluable Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.] Negative mean change is favorable; positive mean change is unfavorable</description>
        <time_frame>8 weeks</time_frame>
        <population>Evaluable Population: Subjects who received at least 80% of the expected amount of study drug if the subject had completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg QD</title>
            <description>Belumosudil 400 mg PO QD for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>200 mg BID</title>
            <description>Belumosudil 200 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>400 mg BID</title>
            <description>Belumosudil 400 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Overall (All Subjects)</title>
            <description>Belumosudil 400 mg QD + 200 mg QD + 400 mg BID for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Mean Change in PASI Score at 4 and 8 Weeks---Evaluable Population</title>
          <description>Mean change in the Psoriasis Area and Severity Index score from baseline after 4 and 8 weeks of treatment with belumosudil in the Evaluable Population.&#xD;
[The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign is assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis.] Negative mean change is favorable; positive mean change is unfavorable</description>
          <population>Evaluable Population: Subjects who received at least 80% of the expected amount of study drug if the subject had completed the study</population>
          <units>Score on a scale</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" lower_limit="-7.8" upper_limit="-1.1"/>
                    <measurement group_id="O2" value="-3.5" lower_limit="-7.2" upper_limit="0.2"/>
                    <measurement group_id="O3" value="-2.7" lower_limit="-8.1" upper_limit="2.7"/>
                    <measurement group_id="O4" value="-3.7" lower_limit="-5.7" upper_limit="-1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" lower_limit="-15.0" upper_limit="-2.1"/>
                    <measurement group_id="O2" value="-6.8" lower_limit="-10.9" upper_limit="-2.7"/>
                    <measurement group_id="O3" value="-4.7" lower_limit="-10.0" upper_limit="0.6"/>
                    <measurement group_id="O4" value="-7.1" lower_limit="-10.2" upper_limit="-3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change in Cohort 400 mg QD from baseline to 4 weeks.</non_inferiority_desc>
            <p_value>0.0140</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change in Cohort 200 mg BID from baseline to 4 weeks.</non_inferiority_desc>
            <p_value>0.0620</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change in 400 mg BID from baseline to 4 weeks.</non_inferiority_desc>
            <p_value>0.2620</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change of all subjects from baseline to 4 weeks.</non_inferiority_desc>
            <p_value>0.0008</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change in Cohort 400 mg QD from baseline to 8 weeks.</non_inferiority_desc>
            <p_value>0.0137</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change in Cohort 200 mg BID from baseline to 8 weeks.</non_inferiority_desc>
            <p_value>0.0064</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change in Cohort 400 mg BID from baseline to 8 weeks.</non_inferiority_desc>
            <p_value>0.0743</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change of all subjects from baseline to 8 weeks.</non_inferiority_desc>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Percentage of Subjects With Improvement in PGA af 4 Weeks---ITT Population</title>
        <description>Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 4 weeks of treatment with belumosudil in the Intent-to-Treat Population.&#xD;
The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement</description>
        <time_frame>4 weeks</time_frame>
        <population>Intent-to-Treat (ITT) Population: All enrolled subjects</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg QD</title>
            <description>Belumosudil 400 mg PO QD for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>200 mg BID</title>
            <description>Belumosudil 200 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>400 mg BID</title>
            <description>Belumosudil 400 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Overall (All Subjects)</title>
            <description>Belumosudil 400 mg QD + 200 mg QD + 400 mg BID for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Percentage of Subjects With Improvement in PGA af 4 Weeks---ITT Population</title>
          <description>Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 4 weeks of treatment with belumosudil in the Intent-to-Treat Population.&#xD;
The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement</description>
          <population>Intent-to-Treat (ITT) Population: All enrolled subjects</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clear/Excellent (75% to 100% Improvement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good (50% to 74% Improvement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="8.3"/>
                    <measurement group_id="O3" value="8.3"/>
                    <measurement group_id="O4" value="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair (25% to 49% Improvement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2"/>
                    <measurement group_id="O2" value="58.3"/>
                    <measurement group_id="O3" value="41.7"/>
                    <measurement group_id="O4" value="48.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Percentage of Subjects With Improvement in PGA af 8 Weeks---ITT Population</title>
        <description>Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 8 weeks of treatment with belumosudil in the Intent-to-Treat Population.&#xD;
The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse.&#xD;
PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement</description>
        <time_frame>8 weeks</time_frame>
        <population>Intent-to-Treat (ITT) Population: All enrolled subjects</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg QD</title>
            <description>Belumosudl 400 mg PO QD for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>200 mg BID</title>
            <description>Belumosudil 200 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>400 mg BID</title>
            <description>Belumosudil 400 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Overall (All Subjects)</title>
            <description>Belumosudil 400 mg QD + 200 mg QD + 400 mg BID for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Percentage of Subjects With Improvement in PGA af 8 Weeks---ITT Population</title>
          <description>Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 8 weeks of treatment with belumosudil in the Intent-to-Treat Population.&#xD;
The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse.&#xD;
PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement</description>
          <population>Intent-to-Treat (ITT) Population: All enrolled subjects</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clear/Excellent (75% to 100% Improvement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good (50% to 74% Improvement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="11.1"/>
                    <measurement group_id="O3" value="14.3"/>
                    <measurement group_id="O4" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair (25% to 49% Improvement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="88.9"/>
                    <measurement group_id="O3" value="42.9"/>
                    <measurement group_id="O4" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Percentage of Subjects With Improvement in PGA af EOT--ITT Population</title>
        <description>Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 12 weeks of treatment with belumosudil or at the end of treatment (EOT) in the Intent-to-Treat Population.&#xD;
The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse.&#xD;
PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement</description>
        <time_frame>12 weeks</time_frame>
        <population>Intent-to-Treat (ITT) Population: All enrolled subjects</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg QD</title>
            <description>Belumosudil 400 mg PO QD for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>200 mg BID</title>
            <description>Belumosudil 200 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>400 mg BID</title>
            <description>Belumosudil 400 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Overall (All Subjects)</title>
            <description>Belumosudil 400 mg PO QD + 200 mg PO QD + 400 mg PO BID for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Percentage of Subjects With Improvement in PGA af EOT--ITT Population</title>
          <description>Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 12 weeks of treatment with belumosudil or at the end of treatment (EOT) in the Intent-to-Treat Population.&#xD;
The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse.&#xD;
PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement</description>
          <population>Intent-to-Treat (ITT) Population: All enrolled subjects</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clear/Excellent (75% to 100% Improvement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good (50% to 74% Improvement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="18.2"/>
                    <measurement group_id="O4" value="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair (25% to 49% Improvement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="36.4"/>
                    <measurement group_id="O4" value="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Percentage of Subjects With Improvement in PGA af 4, 8, and 12 Weeks---Evaluable Population</title>
        <description>Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 4 weeks, after 8 weeks, and after 12 week of treatment with belumosudil in the Evaluable Population.&#xD;
The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse.&#xD;
PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement.</description>
        <time_frame>12 weeks</time_frame>
        <population>Evaluable Population: Subjects who received at least 80% of the expected amount of study drug if the subject had completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg QD</title>
            <description>Belumosudil 400 mg PO QD for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>200 mg BID</title>
            <description>Belumosudil 200 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>400 mg BID</title>
            <description>Belumosudil 400 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Overall (All Subjects)</title>
            <description>Belumosudil 400 mg QD + 200 mg QD + 400 mg BID for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Percentage of Subjects With Improvement in PGA af 4, 8, and 12 Weeks---Evaluable Population</title>
          <description>Percentage of subjects evaluated by the Physician Global Assessment who improve (excellent, good, or fair) from baseline after 4 weeks, after 8 weeks, and after 12 week of treatment with belumosudil in the Evaluable Population.&#xD;
The relative PGA documents the physician's assessment of the subject's psoriasis status. Consideration was given to the percent of body involvement as well as overall induration, scaling, and erythema. The PGA was assessed relative to baseline condition and was defined as: (1) clear; (2) excellent; (3) good; (4) fair; (5) poor; and (6) worse.&#xD;
PGA improvement is defined as the categorical change from baseline: Clear = 100% improvement; Excellent = 75% to 99% improvement; Good = 50% to 74% improvement; Fair = 25% to 49% improvement.</description>
          <population>Evaluable Population: Subjects who received at least 80% of the expected amount of study drug if the subject had completed the study</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 Weeks: Clear/Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks: Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="14.3"/>
                    <measurement group_id="O4" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks: Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7"/>
                    <measurement group_id="O2" value="85.7"/>
                    <measurement group_id="O3" value="42.9"/>
                    <measurement group_id="O4" value="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Weeks: Clear/Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Weeks: Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="14.3"/>
                    <measurement group_id="O4" value="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Weeks: Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="42.9"/>
                    <measurement group_id="O4" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks: Clear/Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks: Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="28.6"/>
                    <measurement group_id="O4" value="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks: Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="85.7"/>
                    <measurement group_id="O3" value="28.6"/>
                    <measurement group_id="O4" value="46.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Mean Changes in DLQI at EOT--ITT Population</title>
        <description>Mean changes in the Dermatology Life Quality Index from baseline after 12 weeks of treatment with belumosudil or end of treatment with KD025 in the Intent-to-Treat Population [The Dermatology Life Quality Index (DLQI) is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. The scale range is 0 to 30: 0-1=no effect on subject's quality of life; 2-5=small effect; 6-10= moderate effect; 11-20=very large effect; 21-30=extremely large effect.] Negative mean change is favorable; positive mean change is unfavorable</description>
        <time_frame>12 weeks</time_frame>
        <population>Intent-to-Treat: All enrolled subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg QD</title>
            <description>Belumosudil 400 mg PO QD for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>200 mg BID</title>
            <description>Belumosudil 200 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>400 mg BID</title>
            <description>Belumosudil 400 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Overall (All Subjects)</title>
            <description>Belumosudil 400 mg QD + 200 mg QD + 400 mg BID for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Mean Changes in DLQI at EOT--ITT Population</title>
          <description>Mean changes in the Dermatology Life Quality Index from baseline after 12 weeks of treatment with belumosudil or end of treatment with KD025 in the Intent-to-Treat Population [The Dermatology Life Quality Index (DLQI) is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. The scale range is 0 to 30: 0-1=no effect on subject's quality of life; 2-5=small effect; 6-10= moderate effect; 11-20=very large effect; 21-30=extremely large effect.] Negative mean change is favorable; positive mean change is unfavorable</description>
          <population>Intent-to-Treat: All enrolled subjects.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="4.68"/>
                    <measurement group_id="O2" value="-5.1" spread="5.35"/>
                    <measurement group_id="O3" value="-2.5" spread="4.50"/>
                    <measurement group_id="O4" value="-4.2" spread="4.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change in Cohort 400 mg QD from baseline to 12 weeks.</non_inferiority_desc>
            <p_value>0.004</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change in Cohort 200 mg BID from baseline to 12 weeks.</non_inferiority_desc>
            <p_value>0.007</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change in Cohort 400 mg BID from baseline to 12 weeks.</non_inferiority_desc>
            <p_value>0.090</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>No control group was used. Paired t-testing was used to determine the statistical significance of the mean change Overall from baseline to 12 weeks.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Mean Changes in DLQI at 12 Weeks--Evaluable Population</title>
        <description>Mean changes in the Dermatology Life Quality Index (DLQI) score from baseline after 12 weeks of treatment with belumosudil in the Evaluable Population.&#xD;
[The Dermatology Life Quality Index (DLQI) is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. The scale range is 0 to 30: 0-1=no effect on subject's quality of life; 2-5=small effect; 6-10= moderate effect; 11-20=very large effect; 21-30=extremely large effect.] Negative mean change is favorable; positive mean change is unfavorable.</description>
        <time_frame>12 weeks</time_frame>
        <population>Evaluable Population: Subjects who received at least 80% of the expected amount of study drug if the subject had completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg QD</title>
            <description>Belumosudil 400 mg PO QD for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>200 mg BID</title>
            <description>Belumosudil 200 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>400 mg BID</title>
            <description>Belumosudil 400 mg PO BID for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Overall (All Subjects)</title>
            <description>Belumosudil 400 mg PO QD + 200 mg PO QD + 400 mg PO BID for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Mean Changes in DLQI at 12 Weeks--Evaluable Population</title>
          <description>Mean changes in the Dermatology Life Quality Index (DLQI) score from baseline after 12 weeks of treatment with belumosudil in the Evaluable Population.&#xD;
[The Dermatology Life Quality Index (DLQI) is a skin disease-specific instrument designed to assess the impact of the disease on a subject's quality of life. The scale range is 0 to 30: 0-1=no effect on subject's quality of life; 2-5=small effect; 6-10= moderate effect; 11-20=very large effect; 21-30=extremely large effect.] Negative mean change is favorable; positive mean change is unfavorable.</description>
          <population>Evaluable Population: Subjects who received at least 80% of the expected amount of study drug if the subject had completed the study</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="4.68"/>
                    <measurement group_id="O2" value="-6.3" spread="5.82"/>
                    <measurement group_id="O3" value="-2.3" spread="2.93"/>
                    <measurement group_id="O4" value="-4.6" spread="4.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.029</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.084</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.001</p_value>
            <p_value_desc>Statistical significance was set at p ≤ 0.05. No adjustments for multiplicity were made. Missing data were not imputed.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Cmax of Parent Drug KD025, KD025m1, and KD025m2</title>
        <description>Maximum concentration (Cmax) of Parent drug (KD0250), Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2)</description>
        <time_frame>24 hours</time_frame>
        <population>PK Population: Subjects received at least 1 dose of study drug and had at least 1 post-dose PK sample drawn.&#xD;
Note: Not all subjects had all data available for PK parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg QD</title>
            <description>Belumosudil 400 mg administered QD (once daily)</description>
          </group>
          <group group_id="O2">
            <title>200 mg BID</title>
            <description>Belumosudil 200 mg administered PO BID (twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Cmax of Parent Drug KD025, KD025m1, and KD025m2</title>
          <description>Maximum concentration (Cmax) of Parent drug (KD0250), Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2)</description>
          <population>PK Population: Subjects received at least 1 dose of study drug and had at least 1 post-dose PK sample drawn.&#xD;
Note: Not all subjects had all data available for PK parameters.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>KD025</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3140" spread="1760"/>
                    <measurement group_id="O2" value="1770" spread="1190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KD025m1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" spread="9.66"/>
                    <measurement group_id="O2" value="22.8" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KD025m2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="632" spread="278"/>
                    <measurement group_id="O2" value="203" spread="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: AUC of Parent Drug KD025, KD025m1, and KD025m2</title>
        <description>Area Under Concentration Time Curve (AUC) for Parent Drug KD025, Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2):&#xD;
AUC(0-12) = AUC from predose to 12 hours post-dose AUC(0-24) = AUC from predose to 24 hours post-dose AUC(0-t) = AUC from predose to a given time &quot;t&quot; post-dose</description>
        <time_frame>24 hours</time_frame>
        <population>PK Population: Subjects received at least 1 dose of study drug and had at least 1 post-dose PK sample drawn.&#xD;
Note: KD025m2 did not have AUC(0-12) or AUC(0-24) available. Not all subjects had all PK measurements. AUC(0-12) and AUC(0-24) for KD025m1 were not calculable.</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg QD</title>
            <description>Belumosudil 400 mg administered QD (once daily)</description>
          </group>
          <group group_id="O2">
            <title>200 mg BID</title>
            <description>Belumosudil 200 mg administered PO BID (twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: AUC of Parent Drug KD025, KD025m1, and KD025m2</title>
          <description>Area Under Concentration Time Curve (AUC) for Parent Drug KD025, Metabolite 1 (KD025m1), and Metabolite 2 (KD025m2):&#xD;
AUC(0-12) = AUC from predose to 12 hours post-dose AUC(0-24) = AUC from predose to 24 hours post-dose AUC(0-t) = AUC from predose to a given time &quot;t&quot; post-dose</description>
          <population>PK Population: Subjects received at least 1 dose of study drug and had at least 1 post-dose PK sample drawn.&#xD;
Note: KD025m2 did not have AUC(0-12) or AUC(0-24) available. Not all subjects had all PK measurements. AUC(0-12) and AUC(0-24) for KD025m1 were not calculable.</population>
          <units>hour*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>KD025: AUC(0-12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16200" spread="8910"/>
                    <measurement group_id="O2" value="9150" spread="5950"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KD025m2: AUC(0-12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2300" spread="907"/>
                    <measurement group_id="O2" value="757" spread="823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KD025: AUC(0-24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18800" spread="10600"/>
                    <measurement group_id="O2" value="21800" spread="13900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KD025m2: AUC(0-24)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2510" spread="1180"/>
                    <measurement group_id="O2" value="1790" spread="1850"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KD025: AUC(0-t)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18800" spread="10600"/>
                    <measurement group_id="O2" value="25100" spread="14800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KD025m1: AUC(0-t)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.4" spread="18.1"/>
                    <measurement group_id="O2" value="250" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KD025m2: AUC(0-t)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2550" spread="1080"/>
                    <measurement group_id="O2" value="1960" spread="1950"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: t(1/2) of KD025</title>
        <description>Half-life (t[1/2]) of Parent drug (KD025)</description>
        <time_frame>24 hours</time_frame>
        <population>Subjects received at least 1 dose of study drug and had at least 1 post-dose PK sample drawn.&#xD;
One subject in 200 mg BID cohort did not have t(1/2) data available.</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg QD</title>
            <description>Belumosudil 400 mg administered QD (once daily)</description>
          </group>
          <group group_id="O2">
            <title>200 mg BID</title>
            <description>Belumosudil 200 mg administered PO BID (twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: t(1/2) of KD025</title>
          <description>Half-life (t[1/2]) of Parent drug (KD025)</description>
          <population>Subjects received at least 1 dose of study drug and had at least 1 post-dose PK sample drawn.&#xD;
One subject in 200 mg BID cohort did not have t(1/2) data available.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" spread="2.47"/>
                    <measurement group_id="O2" value="5.13" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: MR C(Max) and MR AUC(0-t) for KD025m1 and KD025m2</title>
        <description>Metabolite-to-parent ratio of maximum concentration (MR C[max]) and metabolite-to-parent ratio of the area under concentration time curve from pre-dose to a given time &quot;t&quot; for Metabolite 1 (KD025m1) and Metabolite 2 (KD025m2)</description>
        <time_frame>24 hours</time_frame>
        <population>The metabolite-to-parent ratio is not applicable to parent drug KD025. Not all subjects had data for all PK parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>400 mg QD</title>
            <description>Belumosudil 400 mg administered QD (once daily)</description>
          </group>
          <group group_id="O2">
            <title>200 mg BID</title>
            <description>Belumosudil 200 mg administered PO BID (twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: MR C(Max) and MR AUC(0-t) for KD025m1 and KD025m2</title>
          <description>Metabolite-to-parent ratio of maximum concentration (MR C[max]) and metabolite-to-parent ratio of the area under concentration time curve from pre-dose to a given time &quot;t&quot; for Metabolite 1 (KD025m1) and Metabolite 2 (KD025m2)</description>
          <population>The metabolite-to-parent ratio is not applicable to parent drug KD025. Not all subjects had data for all PK parameters.</population>
          <units>Number (ratio)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>KD025m1: MR C(max)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00736" spread="0.00272"/>
                    <measurement group_id="O2" value="0.00984" spread="0.00287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KD025m2: MR C(max)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.199" spread="0.0794"/>
                    <measurement group_id="O2" value="0.101" spread="0.0469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KD025m1: MR AUC(0-t)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00458" spread="0.00253"/>
                    <measurement group_id="O2" value="0.00577" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KD025m2: MR AUC(0-t)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.133" spread="0.0449"/>
                    <measurement group_id="O2" value="0.0719" spread="0.0336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Screening Period ≤ 4 week Screening Period + 12-week Treatment Period + 30-day Follow-up = Up to 20 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>400 mg QD</title>
          <description>Belumosudil 400 mg PO QD for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>200 mg BID</title>
          <description>Belumosudil 200 mg PO BID for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>400 mg BID</title>
          <description>Belumosudil 400 mg PO BID for 12 weeks</description>
        </group>
        <group group_id="E4">
          <title>Overall (All Subjects)</title>
          <description>Belumosudil 400 mg QD + 200 mg QD + 400 mg BID for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hematochezia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Edema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Tonsilitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="6" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="6" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Alanine aminotransaminase (ALT) increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase (AST) increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hyperlipidemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anorgasmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Paransal sinus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Skin discoloration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding results. The sponsor cannot require changes to the study results in the communication except to remove sponsor's confidential information. Sponsor cannot unilaterally extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate VP, Clinical Operations</name_or_title>
      <organization>Kadmon Corporation, LLC</organization>
      <phone>833-900-5366</phone>
      <email>karin.herrera@kadmon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

